Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous gamma-globinG16D/sh RNA734 gene-transduced CD34-positive cells CSL200

A preparation of autologous, CD34-positive hematopoietic stem cells (HSCs) transduced ex vivo with a lentiviral vector encoding for an engineered form of human gamma-globin (hemoglobin-gamma) gene, gamma-globin G16D, and a short-hairpin (sh) RNA734, with potential to restore gamma-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow and the cells are transduced with the lentiviral vector. Upon re-infusion of the CD34-positive cells back into the patient, these cells express gamma-globinG16D, thereby replacing defective beta globin chains with gamma globin chains allowing the body to make fetal hemoglobin (HbF) and thus healthy red blood cells with a greater oxygen-carrying capacity. Gamma-globin comprises is the gamma-chain of HbF; reactivation of HbF in disorders where beta-globin is defective in adult hemoglobin (HbA), such as sickle cell disease and beta thalassemia, may ameliorate these conditions. The G16D form of gamma-globin has increased anti-sickling activity compared to the wild type protein. The shRNA734 is used for positive gene selection.
Synonym:human gamma-globinG16D/short-hairpin RNA734-transduced CD34-positive cells CSL200
Code name:CSL 200
CSL-200
CSL200
Search NCI's Drug Dictionary